Get the Stockscreener App
3.275
8.80%
0.265
After Hours:
3.23
-0.045
-1.37%
Insight Molecular Diagnostics Inc stock is traded at $3.275, with a volume of 33,706.
It is up +8.80% in the last 24 hours and up +26.45% over the past month.
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx.
See More
Previous Close:
$3.01
Open:
$3.11
24h Volume:
33,706
Relative Volume:
1.14
Market Cap:
$93.73M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-1.06%
1M Performance:
+26.45%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$3.03
$3.29
1-Week Range:
$3.01
$3.57
52-Week Range:
$2.33
$3.598
Insight Molecular Diagnostics Inc Stock (IMDX) Company Profile
Name
Insight Molecular Diagnostics Inc
Sector
Industry
Phone
949-409-7600
Address
2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE
Compare IMDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMDX
Insight Molecular Diagnostics Inc
|
3.275 | 86.15M | 0 | 0 | 0 | 0.00 |
|
TMO
Thermo Fisher Scientific Inc
|
468.00 | 177.38B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
185.91 | 135.85B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
627.17 | 51.87B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
124.38 | 35.70B | 6.79B | 1.22B | 1.09B | 4.26 |
|
IQV
Iqvia Holdings Inc
|
181.24 | 31.70B | 15.70B | 1.24B | 2.01B | 6.91 |
Insight Molecular Diagnostics Inc Stock (IMDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-28-25 | Initiated | Lake Street | Buy |
| May-24-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Mar-14-22 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Mar-17-21 | Resumed | Needham | Buy |
| Jan-07-21 | Upgrade | The Benchmark Company | Speculative Buy → Buy |
| Dec-16-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-30-20 | Initiated | BTIG Research | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Jul-30-20 | Reiterated | The Benchmark Company | Speculative Buy |
| Jul-01-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jun-30-20 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jun-02-20 | Initiated | Needham | Buy |
| Feb-13-19 | Initiated | Piper Jaffray | Overweight |
| Jan-29-19 | Upgrade | Janney | Neutral → Buy |
| Dec-19-18 | Resumed | Lake Street | Buy |
View All
Insight Molecular Diagnostics Inc Stock (IMDX) Latest News
Molecular Diagnostics in Pharmacogenomics Market to Reach USD - openPR.com
HOLX to Discontinue Fluoroscan InSight FD Soon: Will the Stock Suffer? - TradingView
Insight Molecular Diagnostics (IMDX) Highlights GraftAssur at In - GuruFocus
Insight Molecular Diagnostics to Showcase Leadership in - GlobeNewswire
Insight Molecular Diagnostics Approves Executive Salary Increases - TipRanks
Co-Diagnostics, Inc. Signs Strategic MOU with Partner in Kingdom of Saudi Arabia to Introduce Co-Dx™ PCR Platform to Middle East - Quantisnow
North America In Vitro Diagnostics (IVD) Market Insights and Future Outlook - openPR.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Lake Street Remains a Buy on Insight Molecular Diagnostics (IMDX) - The Globe and Mail
iMDx launches 5,000-patient registry to study transplant rejection test - Investing.com
iMDx launches 5,000-patient registry to study transplant rejection test By Investing.com - Investing.com Nigeria
Insight Molecular Diagnostics (IMDX) Launches New Patient Regist - GuruFocus
IMDX Advances GraftAssureDx Clinical Trial for Transplant Rejection Test - GuruFocus
Insight Molecular Diagnostics Inc. Enrolls First Patient in GraftAssureDx Clinical Trial and Welcomes New Hospital Participants - MarketScreener
IMDX Enrolls First Patient in GraftAssureDx Clinical Trial and Welcomes New Hospital Participants - GlobeNewswire
Insight Molecular Diagnostics Announces Positive Strategic Update and Novel Registry Database - The Manila Times
Insight Molecular Diagnostics Inc. shares rise 1.62% premarket after Myriad Genetics announces positive MRD test results. - AInvest
Molecular Diagnostics Market: Applications, Growth, and Future Trends - newstrail.com
Insight Molecular Diagnostics Inc. shares rise 1.78% intraday after QIAGEN gains U.S. clearance for higher-throughput syndromic testing system. - AInvest
iMDx to Participate in NYC Investment Conferences September 811 - GlobeNewswire
iMDx Announces Participation in NYC Investment Conferences - AInvest
Molecular Diagnostics Leader iMDx Announces Double-Header NYC Investor Conference Schedule for September - Stock Titan
iMDx CFO Andrea James discusses democratizing molecular diagnostics in podcast episode. - AInvest
IMDX CFO Andrea James Featured in Empowered Patient Podcast on Democratizing Molecular Diagnostics - MarketScreener
HIV Diagnostics Market Size, Share & Forecast, 2025–2034 - Global Market Insights Inc.
Global Minimal Residual Disease Testing Market Gearing Up for Outstanding Expansion at a CAGR of ~11% by 2032 | DelveInsight - PR Newswire UK
Insight Molecular Diagnostics: Pioneering the Next Generation of Transplant Rejection Testing and FDA Readiness - AInvest
Veterinary Molecular Diagnostics Market on Track for Massive Expansion by 2035, Forecasts Reveal. - newstrail.com
Analysts Offer Insights on Healthcare Companies: Immatics (IMTX) and Insight Molecular Diagnostics (IMDX) - The Globe and Mail
Sepsis Diagnostics Market Poised for Remarkable Expansion by 2035, Reveals Prophecy Market Insights Study - newstrail.com
Insight Molecular Diagnostics Inc. shares rise 12.92% intraday after Myriad Genetics appoints new CFO. - AInvest
Molecular Diagnostics Market Evolving Rapidly from 2025 to 2032 | F. Hoffmann-La Roche Ltd, Illumina, Inc. - openPR.com
Insight Molecular: Needham Reiterates Buy Rating with $4.25 PT - AInvest
Lake Street Maintains Insight Molecular Diagnostics(IMDX.US) With Buy Rating, Maintains Target Price $8 - 富途牛牛
Insight Molecular Diagnostics: Paving the Next Frontier in Transplant Rejection Testing with FDA-Ready Innovation - AInvest
IMDX’s GraftAssureDx Study: A Game-Changer in Kidney Transplant Monitoring? - TipRanks
Insight Molecular Diagnostics Inc. shares rise 1.21% intraday after Caris Life Sciences validates MI Cancer Seek® assay. - AInvest
Insight Molecular Diagnostics Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - simplywall.st
Insight Molecular Diagnostics : With Q&A (insight molecular diagnostics inc imdx us q2 2025 earnings call 11 august 2025 5 00 pm et) - MarketScreener
Lake Street Sticks to Their Buy Rating for Insight Molecular Diagnostics (IMDX) - The Globe and Mail
In Vitro Diagnostics Market to Hit USD 197.06 Billion by 2032, Driven by a Surge in Chronic and Infectious Disease Burden | Coherent Market Insights - BioSpace
Insight Molecular Diagnostics Inc. shares fall 1.53% intraday after reporting a Q2 loss of $9.7 million. - AInvest
Insight Molecular Diagnostics Inc (IMDX) Q2 2025 Earnings Call Highlights: Strategic Advances ... - Yahoo Finance
Needham reiterates Buy rating on Insight Molecular Diagnostics stock By Investing.com - Investing.com Nigeria
Needham reiterates Buy rating on Insight Molecular Diagnostics stock - Investing.com India
Insight Molecular Diagnostics: Promising Future with GraftAssureIQ and Strategic Expansion - TipRanks
Insight Molecular Diagnostics: Q2 Earnings Snapshot - Connecticut Post
Insight Molecular Diagnostics Reports Q2 2025 Progress - TipRanks
IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch - Santé log
Earnings call transcript: Insight Molecular Diagnostics Q2 2025 reveals strategic advancements - Investing.com Canada
Insight Molecular Diagnostics Reports Q2 Loss of $9.7 Million - AInvest
Insight Molecular Diagnostics Inc Stock (IMDX) Financials Data
There is no financial data for Insight Molecular Diagnostics Inc (IMDX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
2.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):